The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Myeloproliferative Neoplasms: Molecular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies
Abstract
To update oncologists on pathogenesis, contemporary diagnosis, risk stratification, and treatment strategies in BCR-ABL1–negative myeloproliferative neoplasms, including polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Recent literature was reviewed and interpreted in the context of the authors' own experience and expertise. Pathogenetic mechanisms in PV, ET, and PMF include stem cell–derived clonal myeloproliferation and secondary stromal changes in the bone marrow and spleen. Most patients carry an activating JAK2 or MPL mutation and a smaller subset also harbors LNK, CBL, TET2, ASXL1, IDH, IKZF1, or EZH2 mutations; the precise pathogenetic contribution of these mutations is under investigation. JAK2 mutation analysis is now a formal component of diagnostic criteria for PV, ET, and PMF, but its prognostic utility is limited. Life expectancy in the majority of patients with PV or ET is near-normal and disease complications are effectively (and safely) managed by treatment with low-dose aspirin, phlebotomy, or hydroxyurea. In PMF, survival and quality of life are significantly worse and current therapy is inadequate. In ET and PV, controlled studies are needed to show added value and justify the risk of unknown long-term health effects associated with nonconventional therapeutic approaches (eg, interferon-alfa). The unmet need for treatment in PMF dictates a different approach for assessing the therapeutic value of new drugs (eg, JAK inhibitors, pomalidomide) or allogeneic stem-cell transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vardiman, J. W., Thiele, J., Arber, D. A., Brunning, R. D., Borowitz, M. J., Porwit, A., Harris, N. L., Le Beau, M. M., Hellström-Lindberg, E., Tefferi, A., et al. (2009) · Blood · doi:10.1182/blood-2009-03-209262 · Cited by 4,424
Self-citationAcquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
Self-citationA Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Self-citationMutation in TET2 in Myeloid Cancers
Delhommeau, F., Dupont, S., Valle, V. D., James, C., Trannoy, S., Massé, A., Kosmider, O., Le Couedic, J.-P., Robert, F., Alberdi, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810069 · Cited by 1,776 · cited 3×
“TET2 (TET oncogene family member 2; 4q24) mutations are seen in both JAK2V617F positive and negative MPN with mutational frequencies of approximately 16% in PV, 5% in ET, 17% in PMF, 14% in post-PV MF, 14% in post-ET MF, and 17% in blast phase MPN. 12,33 TET2 mutations in MPN can either antedate or follow the acquisit…”
BackgroundInfluentialSelf-citationMPLW515L Is a Novel Somatic Activating Mutation in Myelofibrosis with Myeloid Metaplasia
Pikman, Y., Lee, B. H., Mercher, T., McDowell, E., Ebert, B. L., Gozo, M., Cuker, A., Wernig, G., Moore, S., Galinsky, I., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030270 · Cited by 1,449
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,276
Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J. T., Morra, E., Vannucchi, A. M., Mesa, R. A., Demory, J.-L., Barosi, G., et al. (2009) · Blood · doi:10.1182/blood-2008-07-170449 · Cited by 1,255
Self-citationSafety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis
Verstovsek, S., Kantarjian, H., Mesa, R. A., Pardanani, A. D., Cortes-Franco, J., Thomas, D. A., Estrov, Z., Fridman, J. S., Bradley, E. C., Erickson-Viitanen, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002028 · Cited by 1,164
Self-citationInactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
Ernst, T., Chase, A. J., Score, J., Hidalgo-Curtis, C. E., Bryant, C., Jones, A. V., Waghorn, K., Zoi, K., Ross, F. M., Reiter, A., et al. (2010) · Nature Genetics · doi:10.1038/ng.621 · Cited by 1,139 · cited 3×
“A recent study described homozygous EZH2 mutations in nine of 12 individuals with 7q acquired uniparental disomy.(20) Among 614 patients with myeloid disorders, 42 harbored 49 monoallelic or biallelic EZH2 mutations.”
BackgroundInfluentialEditorial: Some Speculations on the Myeloproliferative Syndromes
DAMESHEK, W. (1951) · Blood · doi:10.1182/blood.v6.4.372.372 · Cited by 1,082
BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros
Mullighan, C. G., Miller, C. B., Radtke, I., Phillips, L. A., Dalton, J., Ma, J., White, D., Hughes, T. P., Le Beau, M. M., Pui, C.-H., et al. (2008) · Nature · doi:10.1038/nature06866 · Cited by 1,072 · cited 1×
“IKAROS Family Zinc Finger 1 Mutations IKAROS family zinc finger 1 (IKZF1; 7p12) mutations are prevalent in blast phase CML or BCR-ABL1–positive ALL, suggesting a pathogenetic contribution to leukemic transformation.(40) A recent study in BCR-ABL1–negative MPN revealed a 19% and less than 0.”
BackgroundMPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients
Pardanani, A. D., Levine, R. L., Lasho, T., Pikman, Y., Mesa, R. A., Wadleigh, M., Steensma, D. P., Elliott, M. A., Wolanskyj, A. P., Hogan, W. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-018879 · Cited by 1,056
Self-citationGangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.2446 · Cited by 1,055
Self-citationEfficacy and Safety of Low-Dose Aspirin in Polycythemia Vera
Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C., & Barbui, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa035572 · Cited by 1,012
Passamonti, F., Cervantes, F., Vannucchi, A. M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., et al. (2010) · Blood · doi:10.1182/blood-2009-09-245837 · Cited by 994
Self-citationHydroxyurea Compared with Anagrelide in High-Risk Essential Thrombocythemia
Harrison, C. N., Campbell, P. J., Buck, G., Wheatley, K., East, C. L., Bareford, D., Wilkins, B. S., van der Walt, J. D., Reilly, J. T., Grigg, A. P., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043800 · Cited by 927
Tefferi, A., Thiele, J., Orazi, A., Kvasnicka, H. M., Barbui, T., Hanson, C. A., Barosi, G., Verstovsek, S., Birgegard, G., Mesa, R., et al. (2007) · Blood · doi:10.1182/blood-2007-04-083501 · Cited by 862
Self-citationHydroxyurea for Patients with Essential Thrombocythemia and a High Risk of Thrombosis
Cortelazzo, S., Finazzi, G., Ruggeri, M., Vestri, O., Galli, M., Rodeghiero, F., & Barbui, T. (1995) · New England Journal of Medicine · doi:10.1056/nejm199504273321704 · Cited by 843
Kiladjian, J.-J., Cassinat, B., Chevret, S., Turlure, P., Cambier, N., Roussel, M., Bellucci, S., Grandchamp, B., Chomienne, C., & Fenaux, P. (2008) · Blood · doi:10.1182/blood-2008-03-143537 · Cited by 583
Gelsi‐Boyer, V., Trouplin, V., Adélaïde, J., Bonansea, J., Cervera, N., Carbuccia, N., Lagarde, A., Prebet, T., Nezri, M., Sainty, D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07697.x · Cited by 564
Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.69 · Cited by 534
Self-citationBarosi, G., Mesa, R. A., Thiele, J., Cervantes, F., Campbell, P. J., Verstovsek, S., Dupriez, B., Levine, R. L., Passamonti, F., Gotlib, J., et al. (2008) · Leukemia · doi:10.1038/sj.leu.2404914 · Cited by 502
Self-citationPassamonti, F., Rumi, E., Pungolino, E., Malabarba, L., Bertazzoni, P., Valentini, M., Orlandi, E., Arcaini, L., Brusamolino, E., Pascutto, C., et al. (2004) · The American Journal of Medicine · doi:10.1016/j.amjmed.2004.06.032 · Cited by 447
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Tiedt, R., Hao-Shen, H., Sobas, M. A., Looser, R., Dirnhofer, S., Schwaller, J., & Skoda, R. C. (2008) · Blood · doi:10.1182/blood-2007-08-107748 · Cited by 440
Finazzi, G. (2005) · Blood · doi:10.1182/blood-2004-09-3426 · Cited by 431
MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort
Beer, P. A., Campbell, P. J., Scott, L. M., Bench, A. J., Erber, W. N., Bareford, D., Wilkins, B. S., Reilly, J. T., Hasselbalch, H. C., Bowman, R., et al. (2008) · Blood · doi:10.1182/blood-2008-01-131664 · Cited by 431
Voskaridou, E., Christoulas, D., Bilalis, A., Plata, E., Varvagiannis, K., Stamatopoulos, G., Sinopoulou, K., Balassopoulou, A., Loukopoulos, D., & Terpos, E. (2010) · Blood · doi:10.1182/blood-2009-05-221333 · Cited by 430
Quintás-Cardama, A., Kantarjian, H., Manshouri, T., Luthra, R., Estrov, Z., Pierce, S., Richie, M. A., Borthakur, G., Konopleva, M., Cortes, J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.6075 · Cited by 428
Tefferi, A., Pardanani, A., Lim, K.-H., Abdel-Wahab, O., Lasho, T. L., Patel, J., Gangat, N., Finke, C. M., Schwager, S., Mullally, A., et al. (2009) · Leukemia · doi:10.1038/leu.2009.47 · Cited by 425
Self-citationSafety and Efficacy of TG101348, a Selective JAK2 Inhibitor, in Myelofibrosis
Pardanani, A., Gotlib, J. R., Jamieson, C., Cortes, J. E., Talpaz, M., Stone, R. M., Silverman, M. H., Gilliland, D. G., Shorr, J., & Tefferi, A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.8021 · Cited by 400
Self-citationKröger, N., Holler, E., Kobbe, G., Bornhäuser, M., Schwerdtfeger, R., Baurmann, H., Nagler, A., Bethge, W., Stelljes, M., Uharek, L., et al. (2009) · Blood · doi:10.1182/blood-2009-07-234880 · Cited by 396
Grand, F. H., Hidalgo-Curtis, C. E., Ernst, T., Zoi, K., Zoi, C., McGuire, C., Kreil, S., Jones, A., Score, J., Metzgeroth, G., et al. (2009) · Blood · doi:10.1182/blood-2008-12-194548 · Cited by 378
Passamonti, F., Rumi, E., Pietra, D., Elena, C., Boveri, E., Arcaini, L., Roncoroni, E., Astori, C., Merli, M., Boggi, S., et al. (2010) · Leukemia · doi:10.1038/leu.2010.148 · Cited by 370
Mutations of ASXL1 gene in myeloproliferative neoplasms
Carbuccia, N., Murati, A., Trouplin, V, Brecqueville, M., Adélaïde, J., Rey, J., Vainchenker, W., Bernard, O. A., Chaffanet, M., Vey, N., et al. (2009) · Leukemia · doi:10.1038/leu.2009.141 · Cited by 331
Self-citationOh, S. T., Simonds, E. F., Jones, C., Hale, M. B., Goltsev, Y., Gibbs, K. D., Merker, J. D., Zehnder, J. L., Nolan, G. P., & Gotlib, J. (2010) · Blood · doi:10.1182/blood-2010-02-270108 · Cited by 330
Abdel-Wahab, O., Manshouri, T., Patel, J., Harris, K., Yao, J., Hedvat, C., Heguy, A., Bueso-Ramos, C., Kantarjian, H., Levine, R. L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3783 · Cited by 326
Tefferi, A., Lasho, T. L., Abdel-Wahab, O., Guglielmelli, P., Patel, J., Caramazza, D., Pieri, L., Finke, C. M., Kilpivaara, O., Wadleigh, M., et al. (2010) · Leukemia · doi:10.1038/leu.2010.113 · Cited by 318
Self-citationPietra, D., Li, S., Brisci, A., Passamonti, F., Rumi, E., Theocharides, A., Ferrari, M., Gisslinger, H., Kralovics, R., Cremonesi, L., et al. (2008) · Blood · doi:10.1182/blood-2007-07-101576 · Cited by 298
Pardanani, A., Lasho, T. L., Finke, C., Hanson, C. A., & Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404810 · Cited by 298
Self-citationNajean, Y., & Rain, J.-D. (1997) · Blood · doi:10.1182/blood.v90.9.3370 · Cited by 297
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Pardanani, A., & Tefferi, A. (2008) · Leukemia · doi:10.1038/leu.2008.113 · Cited by 294
Self-citationScott, L. M., Scott, M. A., Campbell, P. J., & Green, A. R. (2006) · Blood · doi:10.1182/blood-2006-04-018259 · Cited by 294
Mutations in CBL occur frequently in juvenile myelomonocytic leukemia
Loh, M. L., Sakai, D. S., Flotho, C., Kang, M., Fliegauf, M., Archambeault, S., Mullighan, C. G., Chen, L., Bergstraesser, E., Bueso-Ramos, C. E., et al. (2009) · Blood · doi:10.1182/blood-2009-01-198416 · Cited by 286
Somatic Mutations of IDH1 and IDH2 in the Leukemic Transformation of Myeloproliferative Neoplasms
Green, A., & Beer, P. (2010) · New England Journal of Medicine · doi:10.1056/nejmc0910063 · Cited by 285
Mesa, R. A., Steensma, D. P., Pardanani, A., Li, C.-Y., Elliott, M., Kaufmann, S. H., Wiseman, G., Gray, L. A., Schroeder, G., Reeder, T., et al. (2003) · Blood · doi:10.1182/blood-2002-09-2928 · Cited by 283
Self-citationPassamonti, F., Rumi, E., Arcaini, L., Boveri, E., Elena, C., Pietra, D., Boggi, S., Astori, C., BERNASCONI, P. P., Varettoni, M., et al. (2008) · Haematologica · doi:10.3324/haematol.13346 · Cited by 265
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
Tefferi, A., Cortes, J., Verstovsek, S., Mesa, R. A., Thomas, D., Lasho, T. L., Hogan, W. J., Litzow, M. R., Allred, J. B., Jones, D., et al. (2006) · Blood · doi:10.1182/blood-2006-02-004572 · Cited by 253
Self-citationTefferi, A., Lasho, T. L., Huang, J., Finke, C., Mesa, R. A., Li, C. Y., Wu, W., Hanson, C. A., & Pardanani, A. (2008) · Leukemia · doi:10.1038/sj.leu.2405097 · Cited by 251
Self-citationAlvarez-Larrán, A., Cervantes, F., Pereira, A., Arellano-Rodrigo, E., Pérez-Andreu, V., Hernández-Boluda, J.-C., Ayats, R., Salvador, C., Muntañola, A., Bellosillo, B., et al. (2010) · Blood · doi:10.1182/blood-2010-01-263319 · Cited by 244
Passamonti, F., Elena, C., Schnittger, S., Skoda, R. C., Green, A. R., Girodon, F., Kiladjian, J.-J., McMullin, M. F., Ruggeri, M., Besses, C., et al. (2011) · Blood · doi:10.1182/blood-2010-11-316810 · Cited by 236
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia
Vannucchi, A. M., Antonioli, E., Guglielmelli, P., Pancrazzi, A., Guerini, V., Barosi, G., Ruggeri, M., Specchia, G., Lo-Coco, F., Delaini, F., et al. (2008) · Blood · doi:10.1182/blood-2008-01-135897 · Cited by 222
Guglielmelli, P., Barosi, G., Specchia, G., Rambaldi, A., Lo Coco, F., Antonioli, E., Pieri, L., Pancrazzi, A., Ponziani, V., Delaini, F., et al. (2009) · Blood · doi:10.1182/blood-2009-04-216044 · Cited by 215
Gangat, N., Wolanskyj, A. P., McClure, R. F., Li, C.-Y., Schwager, S., Wu, W., & Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404500 · Cited by 208
Self-citationPomalidomide Is Active in the Treatment of Anemia Associated With Myelofibrosis
Tefferi, A., Verstovsek, S., Barosi, G., Passamonti, F., Roboz, G. J., Gisslinger, H., Paquette, R. L., Cervantes, F., Rivera, C. E., Deeg, H. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.7356 · Cited by 195
Self-citationIDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
Pardanani, A., Lasho, T. L., Finke, C. M., Mai, M., McClure, R. F., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.77 · Cited by 184
Self-citationThe haematocrit and platelet target in polycythemia vera
Di Nisio, M., Barbui, T., Di Gennaro, L., Borrelli, G., Finazzi, G., Landolfi, R., Leone, G., Marfisi, R., Porreca, E., Ruggeri, M., et al. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06430.x · Cited by 183
Pardanani, A., Lasho, T., Finke, C., Oh, S. T., Gotlib, J., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.163 · Cited by 182
Self-citationCaramazza, D., Begna, K. H., Gangat, N., Vaidya, R., Siragusa, S., Van Dyke, D. L., Hanson, C., Pardanani, A., & Tefferi, A. (2011) · Leukemia · doi:10.1038/leu.2010.234 · Cited by 178
Self-citationBarbui, T., Carobbio, A., Rambaldi, A., & Finazzi, G. (2009) · Blood · doi:10.1182/blood-2009-02-206797 · Cited by 159
Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
Gangat, N., Strand, J. J., Li, C., Wu, W., Pardanani, A. D., & Tefferi, A. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06674.x · Cited by 157
Self-citationSchaub, F. X., Looser, R., Li, S., Hao-Shen, H., Lehmann, T., Tichelli, A., & Skoda, R. C. (2010) · Blood · doi:10.1182/blood-2009-09-245381 · Cited by 157
Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis.
Mossuz, P., Girodon, F., Donnard, M., Latger‐Cannard, V., Dobo, I., Boiret, N., Lecron, J., Binquet, C., Barro, C. D., Hermouet, S., et al. (2004) · PubMed · Cited by 156
Quintás‐Cardama, A., Kantarjian, H. M., Manshouri, T., Thomas, D. A., Cortes, J. E., Ravandi, F., Garcia‐Manero, G., Ferrajoli, A., Bueso-Ramos, C., & Verstovšek, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.6548 · Cited by 154
Anaemia characterises patients with myelofibrosis harbouring MplW515L/K mutation
Guglielmelli, P., Pancrazzi, A., Bergamaschi, G., Rosti, V., Villani, L., Antonioli, E., Bosi, A., Barosi, G., & Vannucchi, A. M. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06565.x · Cited by 153
LNKMutations inJAK2Mutation–Negative Erythrocytosis
Lasho, T. L., Pardanani, A. D., & Tefferi, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmc1006966 · Cited by 151
Self-citationDeletions of the transcription factor Ikaros in myeloproliferative neoplasms
Jäger, R., Gisslinger, H., Passamonti, F., Rumi, E., Berg, T., Gisslinger, B., Pietra, D., Harutyunyan, A. S., Klampfl, T., Olcaydu, D., et al. (2010) · Leukemia · doi:10.1038/leu.2010.99 · Cited by 148
Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis
James, C., Delhommeau, F., Marzac, C., Teyssandier, I., Couédic, J. L., Giraudier, S., Roy, L., Saulnier, P., Lacroix, L., Maury, S., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404069 · Cited by 144
Self-citationMesa, R. A., Yao, X., Cripe, L. D., Li, C., Litzow, M. R., Paietta, E. M., Rowe, J. M., Tefferi, A., & Tallman, M. S. (2010) · Blood · doi:10.1182/blood-2010-05-287417 · Cited by 138
Self-citationMyeloproliferative neoplasms: contemporary diagnosis using histology and genetics
Tefferi, A., Skoda, R. C., & Vardiman, J. W. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.149 · Cited by 136
Self-citationThe history of myeloproliferative disorders: before and after Dameshek
Tefferi, A. (2007) · Leukemia · doi:10.1038/sj.leu.2404946 · Cited by 127
Self-citationRisk factors for leukemic transformation in patients with primary myelofibrosis
Huang, J., Li, C., Mesa, R. A., et al. (2008) · Cancer · doi:10.1002/cncr.23505 · Cited by 126
Thalidomide treatment in myelofibrosis with myeloid metaplasia
Elliott, M. A., Mesa, R. A., Li, C., Hook, C. C., Ansell, S. M., Levitt, R., Geyer, S. M., & Tefferi, A. (2002) · British Journal of Haematology · doi:10.1046/j.1365-2141.2002.03443.x · Cited by 126
Self-citationTefferi, A., Lasho, T. L., Mesa, R. A., Pardanani, A. D., Ketterling, R. P., & Hanson, C. A. (2007) · Leukemia · doi:10.1038/sj.leu.2404711 · Cited by 124
Self-citationMutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias
Carbuccia, N., Trouplin, V., Gelsi‐Boyer, V., Murati, A., Rocquain, J., Adélaı̈de, J., Olschwang, S., Xerri, L., Vey, N., Chaffanet, M., et al. (2009) · Leukemia · doi:10.1038/leu.2009.218 · Cited by 121
Tam, C. S. L., Kantarjian, H. M., Cortes, J. E., Lynn, A., Pierce, S. A., Zhou, L., Keating, M. J., Thomas, D. A., & Verstovšek, S. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.8833 · Cited by 119
A dynamic prognostic model to predict survival in post–polycythemia vera myelofibrosis
Passamonti, F., Rumi, E., Caramella, M., Elena, C., Arcaini, L., Boveri, E., Curto, C. D., Pietra, D., Vanelli, L., BERNASCONI, P. P., et al. (2008) · Blood · doi:10.1182/blood-2007-11-121434 · Cited by 117
Evidence and expertise in the management of polycythemia vera and essential thrombocythemia
Finazzi, G., & Barbui, T. (2008) · Leukemia · doi:10.1038/leu.2008.177 · Cited by 112
Tefferi, A., Lasho, T. L., Patnaik, M. M., Finke, C. M., Hussein, K., Hogan, W. J., Elliott, M. A., Litzow, M. R., Hanson, C. A., & Pardanani, A. D. (2009) · Leukemia · doi:10.1038/leu.2009.225 · Cited by 105
Self-citationThalidomide therapy for myelofibrosis with myeloid metaplasia
Thomas, D. A., Giles, F. J., Albitar, M. X., Cortes, J. E., Verstovšek, S., Faderl, S. H., O'Brien, S. M., Garcia‐Manero, G., Keating, M. J., Pierce, S. A., et al. (2006) · Cancer · doi:10.1002/cncr.21827 · Cited by 101
Lnk inhibits myeloproliferative disorder-associated JAK2 mutant, JAK2V617F
Gery, S., Cao, Q., Gueller, S., Xing, H., Tefferi, A., & Koeffler, H. P. (2009) · Journal of Leukocyte Biology · doi:10.1189/jlb.0908575 · Cited by 81
Self-citationDingli, D., Schwager, S. M., Mesa, R. A., Li, C., Dewald, G. W., & Tefferi, A. (2006) · Cancer · doi:10.1002/cncr.21868 · Cited by 63
Self-citationPardanani, A. D., Patnaik, M. M., Lasho, T. L., Mai, M., Knudson, R. A., Finke, C. M., Ketterling, R. P., McClure, R. F., & Tefferi, A. (2010) · Leukemia · doi:10.1038/leu.2010.98 · Cited by 62
Self-citationBusulphan is safe and efficient treatment in elderly patients with essential thrombocythemia
Shvidel, L., Sigler, E., Haran, M. Z., Klepfish, A., Duek, A., Berrébi, A., & Shtalrid, M. (2007) · Leukemia · doi:10.1038/sj.leu.2404743 · Cited by 55
Verstovšek, S., Passamonti, F., Rambaldi, A., Barosi, G., Rosen, P. J., Levy, R., Bradley, E. C., Schacter, L., Garrett, W. M., Vaddi, K., et al. (2009) · Blood · doi:10.1182/blood.v114.22.311.311 · Cited by 48
Cited by
Tefferi, A., Guglielmelli, P., Larson, D. R., Finke, C., Wassie, E. A., Pieri, L., Gangat, N., Fjerza, R., Belachew, A. A., Lasho, T. L., et al. (2014) · Blood · doi:10.1182/blood-2014-05-579136 · Cited by 737
Self-citationBarbui, T., Finazzi, G., Carobbio, A., Thiele, J., Passamonti, F., Rumi, E., Ruggeri, M., Rodeghiero, F., Randi, M. L., Bertozzi, I., et al. (2012) · Blood · doi:10.1182/blood-2012-07-444067 · Cited by 604
Self-citationMyeloproliferative neoplasms and thrombosis
Barbui, T., Finazzi, G., & Falanga, A. (2013) · Blood · doi:10.1182/blood-2013-03-460154 · Cited by 415
New mutations and pathogenesis of myeloproliferative neoplasms
Vainchenker, W., Delhommeau, F., Constantinescu, S. N., & Bernard, O. A. (2011) · Blood · doi:10.1182/blood-2011-02-292102 · Cited by 395
Self-citationTefferi, A., Cervantes, F., Mesa, R., Passamonti, F., Verstovsek, S., Vannucchi, A. M., Gotlib, J., Dupriez, B., Pardanani, A., Harrison, C., et al. (2013) · Blood · doi:10.1182/blood-2013-03-488098 · Cited by 386
Self-citation
Metadata
- Authors
- Tefferi, A., & Vainchenker, W.
- Venue
- Journal of Clinical Oncology
- Published
- 2011-02-10
- Volume
- 29
- Issue
- 5
- Pages
- 573-582
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2085325045
- Cited by
- 327
- References
- 86
- FWCI
- 23.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.